Clinical trials: Pituitary Macroadenoma
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Resectable, Non-functioning Pituitary Adenoma
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.
- Trial name
- NCT01203618
- Testing
- Farletuzumab
- Where
- United States
- Sponsor
- Morphotek
Acromegaly
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207…
- Trial name
- NCT01471405
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 54 people
- Sponsor
- Ipsen
Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (> 10 mm).
- Trial name
- NCT00242541
- Testing
- Octreotide acetate
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals